Wealthsource Partners LLC lifted its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,002 shares of the biopharmaceutical company’s stock after purchasing an additional 126 shares during the period. Wealthsource Partners LLC’s holdings in Alexion Pharmaceuticals were worth $365,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Guardian Life Insurance Co. of America grew its holdings in shares of Alexion Pharmaceuticals by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 6 shares during the last quarter. Fiduciary Trust Co. bought a new position in shares of Alexion Pharmaceuticals during the 2nd quarter valued at $111,000. Meeder Asset Management Inc. bought a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at $111,000. Huntington National Bank grew its holdings in shares of Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 987 shares during the last quarter. Finally, Penserra Capital Management LLC grew its holdings in shares of Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the last quarter. 94.25% of the stock is currently owned by institutional investors.

Several equities analysts recently commented on the stock. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Leerink Swann reaffirmed a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $161.00 target price on the stock. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $154.56.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 0.60% during midday trading on Friday, hitting $140.61. 721,653 shares of the stock traded hands. The company has a market cap of $31.38 billion, a price-to-earnings ratio of 60.98 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The firm’s 50-day moving average is $142.11 and its 200-day moving average is $127.08.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. During the same period in the prior year, the business posted $1.13 earnings per share. The business’s revenue for the quarter was up 21.1% on a year-over-year basis. Analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

WARNING: “Wealthsource Partners LLC Acquires 126 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/10/14/wealthsource-partners-llc-acquires-126-shares-of-alexion-pharmaceuticals-inc-alxn.html.

In related news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at $3,738,560. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,190 shares of company stock valued at $2,433,669. 4.35% of the stock is owned by insiders.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.